NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jul 14 04:00PM ET
8.61
Dollar change
-0.10
Percentage change
-1.15
%
Index- P/E- EPS (ttm)-24.46 Insider Own43.95% Shs Outstand8.49M Perf Week3.11%
Market Cap73.72M Forward P/E- EPS next Y-4.69 Insider Trans37.91% Shs Float4.80M Perf Month-4.33%
Enterprise Value-19.95M PEG- EPS next Q-1.11 Inst Own30.16% Short Float1.51% Perf Quarter-6.10%
Income-81.70M P/S6.33 EPS this Y71.62% Inst Trans3.26% Short Ratio4.85 Perf Half Y-32.79%
Sales11.64M P/B12.89 EPS next Y23.74% ROA-107.83% Short Interest0.07M Perf YTD-40.00%
Book/sh0.67 P/C0.73 EPS next 5Y38.93% ROE-456.32% 52W High18.17 -52.61% Perf Year-11.24%
Cash/sh11.87 P/FCF- EPS past 3/5Y2.52% 14.80% ROIC-656.15% 52W Low5.90 45.93% Perf 3Y-82.17%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin88.45% Volatility5.89% 8.19% Perf 5Y-
Dividend TTM- EV/Sales-1.71 EPS Y/Y TTM-33.10% Oper. Margin-223.06% ATR (14)0.67 Perf 10Y-
Dividend Ex-Date- Quick Ratio10.02 Sales Y/Y TTM-20.00% Profit Margin-702.05% RSI (14)48.08 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio10.02 EPS Q/Q-75.36% SMA20-3.15% Beta0.59 Target Price37.00
Payout- Debt/Eq1.41 Sales Q/Q- SMA50-0.08% Rel Volume0.17 Prev Close8.71
Employees41 LT Debt/Eq1.20 EarningsMay 09 AMC SMA200-16.93% Avg Volume14.91K Price8.61
IPOJan 11, 2021 Option/ShortNo / Yes EPS/Sales Surpr.-316.25% - Trades Volume2,566 Change-1.15%
Date Action Analyst Rating Change Price Target Change
Jan-30-25Initiated H.C. Wainwright Buy $32
Jan-03-25Upgrade Guggenheim Neutral → Buy $45
Oct-11-21Initiated BofA Securities Buy $11
Sep-15-21Initiated Guggenheim Buy $20
Sep-07-21Initiated Stifel Buy $19
May-16-25 09:35AM
May-14-25 08:30AM
May-09-25 04:05PM
Mar-31-25 04:05PM
Mar-24-25 09:00AM
04:30PM Loading…
Nov-06-24 04:30PM
09:00AM
Nov-04-24 08:30AM
Sep-24-24 08:30AM
Aug-12-24 04:05PM
Jun-12-24 08:30AM
Jun-10-24 08:30AM
Jun-04-24 08:30AM
May-09-24 08:30AM
May-08-24 11:55PM
04:05PM Loading…
04:05PM
Apr-14-24 12:52PM
Apr-03-24 08:40AM
Apr-01-24 08:30AM
08:30AM
Jan-18-24 09:58AM
08:30AM
Dec-14-23 05:52AM
05:51AM
Nov-08-23 04:05PM
Aug-09-23 04:05PM
Jun-05-23 08:30AM
May-10-23 04:05PM
Apr-05-23 08:30AM
Mar-28-23 04:59AM
04:01PM Loading…
Mar-22-23 04:01PM
Mar-20-23 04:30PM
Jan-04-23 04:41PM
Nov-14-22 04:30PM
Oct-10-22 08:00AM
Oct-06-22 08:00AM
Sep-26-22 08:00AM
Aug-11-22 08:00AM
Jun-27-22 10:34AM
Jun-13-22 08:00AM
May-24-22 08:00AM
May-18-22 08:00AM
May-16-22 08:00AM
May-11-22 08:00AM
May-05-22 08:00AM
May-02-22 08:00AM
Mar-24-22 08:00AM
Jan-20-22 09:00AM
Jan-10-22 08:00AM
Jan-05-22 08:00AM
Nov-15-21 04:00PM
08:00AM
08:00AM
Nov-11-21 10:51AM
Nov-05-21 08:00AM
Oct-05-21 04:30PM
Sep-23-21 08:30AM
Aug-11-21 05:30PM
Surrozen, Inc. is a clinical stage biotechnology company, which engages in the business of discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. The company was founded by K. Christopher Garcia and Roeland Nusse on August 12, 2015 and is headquartered in South San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
COLUMN GROUP III GP, LP10% OwnerMar 26 '25Buy11.601,034,48211,999,991795,411Mar 28 08:57 PM
Li YangExec. Vice President, ResearchJan 03 '25Sale17.3784314,64313,345Jan 06 09:13 PM
Williams Charles OCFO and COOJan 03 '25Sale17.371,18120,5148,982Jan 06 08:07 PM